Arkolith/Insider Trading/KALV/Form 4

Piekos Brian

Chief Financial OfficerKalVista Pharmaceuticals, Inc. (KALV) · full profile →Form 4 · filed May 26, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$40K
Net Open-Market Flow
-$40K
Transactions
3
2 non-derivative · 1 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
May 22, 2026Sell(S)1K$26.78$40K22K
May 21, 2026Option exercise(M)5K——23K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
May 21, 2026Option exercise(M)5K—$055K

Transaction Codes

S
Open-market sale
M
Option exercise / conversion

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001815308-26-000004) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML